Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

CELGENE CORPORATION (CELG)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/11/2018 10/12/2018 10/15/2018 10/16/2018 10/17/2018 Date
80.71(c) 82.58(c) 81.83(c) 84.28(c) 84.28 Last
5 818 611 4 737 358 3 324 839 3 200 517 2 544 138 Volume
-4.18% +2.32% -0.91% +2.99% 0.00% Change
More quotes
Financials (USD)
Sales 2018 15 168 M
EBIT 2018 8 461 M
Net income 2018 4 568 M
Debt 2018 13 270 M
Yield 2018 -
Sales 2019 16 908 M
EBIT 2019 9 623 M
Net income 2019 6 175 M
Debt 2019 6 981 M
Yield 2019 -
P/E ratio 2018 13,56
P/E ratio 2019 10,05
EV / Sales2018 4,70x
EV / Sales2019 3,85x
Capitalization 58 084 M
More Financials
Company
Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases.Its targeting areas include intracellular signaling pathways, protein homeostasis and epigenetics in... 
Sector
Pharmaceuticals
Calendar
10/25Earnings Release
More about the company
Surperformance© ratings of Celgene Corporation
Trading Rating : Investor Rating :
More Ratings
Latest news on CELGENE CORPORATION
10/17ONCOMED PHARMACEUTICALS : Says Celgene Won't Exercise Option to License Rosmantu..
DJ
10/12MANAGEMENT TRACKS : Former Baxalta exec joins VisionGate; Carrick names Golumbes..
AQ
10/11CELGENE : Survey Results Presented at ECTRIMS Reveal People with Multiple Sclero..
BU
10/11CELGENE : BeiGene Announces National Reimbursement Inclusion of VIDAZA (Azacitid..
AQ
10/10CELGENE : Announces Phase 3 STYLE Study of OTEZLA (apremilast) in Moderate to Se..
AQ
10/10CELGENE : New Analyses from Pivotal Phase 3 Trials of Oral Ozanimod to Be Presen..
BU
10/10CELGENE : Versant-backed Gotham raises $54M series A
AQ
10/09FDA, EMA to review Novartis' siponimod for secondary progressive MS
AQ
10/08CELGENE : Says Phase 3 Study of Otezla Met Primary Endpoint
DJ
10/08CELGENE : Announces Phase 3 STYLE Study of OTEZLA® (apremilast) in Moderate to S..
BU
More news
Sector news : Pharmaceuticals - NEC
12:31aCorona maker's CEO Rob Sands to step down, insider to replace him
RE
10/17Health Care Up On Stronger Earnings -- Health Care Roundup
DJ
10/17PFIZER : Looks to Reduce Headcount by 2%--Reports
DJ
10/17PFIZER : to cut around 2 percent of jobs through early next year
RE
10/17ANTHEM : HealthCore, Novo Nordisk to Study Diabetes Treatment Compared With Othe..
DJ
More sector news : Pharmaceuticals - NEC
MarketScreener Strategies on CELGENE CORPORATION 
CELGENE CORPORATION - 2017
The resistance should give in
BUY
CELGENE CORPORATION - 2017
Hesitation should subside in favor of volatility
BUY
More Strategies
Latest Tweets
12:47aOncomed Pharmaceuticals : Says Celgene Won't Exercise Option to License Rosma.. 
10/17OncoMed Pharma down 8% after hours on Celgene withdrawal from rosmantuzumab  
10/17Trading Ideas: $CELG Celgene LT Downtrend - $20M Bearish Options Bet ? FREE .. 
10/17Brokerages Set Celgene Co. $CELG Price Target at $120.99  
10/17Leerink Swann Sets Celgene FY2018 Earnings Estimates at $7.96 EPS.  
More tweets
Qtime:187
News from SeekingAlpha
10/17OncoMed Pharma down 8% after hours on Celgene withdrawal from rosmantuzumab 
10/16ONCOMED : Undervalued With A Promising Pipeline 
10/15FDA issues new guidance aimed at more efficient drug development 
10/15Protect Your Portfolio And Increase Returns By Focusing On Earnings Trends 
10/11The October Pause That Refreshes 
Chart CELGENE CORPORATION
Duration : Period :
Celgene Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 112 $
Spread / Average Target 32%
EPS Revisions
Managers
NameTitle
Mark J. Alles Chairman, President, CEO & COO
David V. Elkins Chief Financial Officer & Executive Vice President
Joseph S. Camardo Senior Vice President-Global Medical Affairs
Jay T. Backstrom Chief Medical Officer
Rupert J. Vessey President-Research & Early Development
Sector and Competitors
1st jan.Capitalization (M$)
CELGENE CORPORATION-21.59%58 084
JOHNSON & JOHNSON-4.19%359 141
PFIZER20.87%256 643
NOVARTIS0.07%212 170
ROCHE HOLDING LTD.-4.56%204 777
MERCK AND COMPANY23.44%185 661